Back to today’s briefing

Story perspectives

CSL Secures FDA Approval for Breakthrough HAE Treatment

6/17/2025

26 2

Summary

Story summary

CSL has achieved a significant milestone with FDA approval for Andembry, a groundbreaking treatment for hereditary angioedema (HAE) in patients aged 12 and up. Set to launch in the US by June 2025, this innovative therapy not only marks a triumph for CSL but also boosts its standing in the rare disease market worldwide.

1 of 1

Story summary

CSL has achieved a significant milestone with FDA approval for Andembry, a groundbreaking treatment for hereditary angioedema (HAE) in patients aged 12 and up. Set to launch in the US by June 2025, this innovative therapy not only marks a triumph for CSL but also boosts its standing in the rare disease market worldwide.